Navigation Links
Boston Scientific Announces Global Launch of Journey™ Guidewire
Date:10/13/2010

NATICK, Mass., Oct. 13 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the global launch of its Journey™ Guidewire, an innovative 0.014" guidewire designed for use in challenging, small vessel peripheral angioplasty procedures.  The Journey Guidewire strengthens Boston Scientific's broad portfolio of devices designed to address physician needs in treating arteries below the knee.  

James Benenati, M.D., Medical Director of the Baptist Cardiac and Vascular Institute in Miami, and President of the Society of Interventional Radiology, has performed some of the initial procedures using the new Journey Guidewire, including a live case at the recent Transcatheter Cardiovascular Therapeutics scientific symposium.

"In my experience, the Journey Guidewire provides exceptional torque and flexibility, particularly in difficult cases involving small vessels or tortuous anatomy," said Dr. Benenati.  "This highly durable guidewire offers outstanding precision and tracking to help access the toughest peripheral lesions."

Guidewires are thin, flexible wires used to facilitate the placement of balloon catheters or other therapeutic devices.  The Journey Guidewire builds on Boston Scientific's advanced guidewire technology used in coronary and neurovascular interventions.  It features a micro-cut nitinol sleeve designed to provide efficient transmission of torque energy for more precise turn-by-turn response and control compared to conventional spring-coil guidewires.  The nitinol distal core and hydrophilic coating are designed to enhance wire durability, tactile response and device delivery for improved overall performance.

"The Journey Guidewire reflects Boston Scientific's commitment to providing physicians the most advanced solutions for peripheral interventions," said Joe Fitzgerald, Senior Vice President
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
2. Boston Scientific Welcomes Publication of Analysis Demonstrating Long-Term Survival Benefit for ICD Therapy
3. Boston Scientifics TAXUS® Element™ Stent Demonstrates Strong Outcomes in Diabetic Patients
4. Boston Scientific Announces Clinical Data Supporting Safety and Efficacy of Platinum Chromium PROMUS Element™ Stent
5. Boston Scientific to Acquire Asthmatx
6. Boston Scientific Receives Exclusive Expanded Indication for Its CRT-Ds
7. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
8. Boston Millennia Partners Portfolio Company CardioMEMS Signs Equity Investment and Exclusive Option to be Acquired for an Additional $375,000,000
9. Childrens Hospital Boston and Particle Sciences Cooperate on Translational Medicine Efforts
10. Boston Scientifics Womens Health Products Featured in Studies at the Joint Annual Meeting of the International Continence Society and International Urogynecological Association
11. Boston Scientific Launches Neuroform EZ(TM) Stent System in U.S. and Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... 2014 financial results after the Nasdaq market closes on ... live conference call and webcast to discuss its financial ... 7, 2014 at 8:00 a.m. Eastern Time (5:00 a.m. ... conference call by dialing 866-952-1907 (US) or 785-424-1826 (International) ...
(Date:7/29/2014)... Research and Markets has announced the addition ... report to their offering. ... medical device used to provide medication or assist a ... achieve adequate oxygen levels to maintain life. Patients with ... ARDS require the need of respiratory devices. The medication ...
(Date:7/29/2014)... 2014 Cynosure, Inc. (Nasdaq: ... light-based aesthetic treatment systems for high-volume applications, today reported ... 2014. Second-quarter 2014 financial results incorporate the acquisition of ... 2013. Second-Quarter 2014 Financial Highlights ... $72.6 million , Non-GAAP net income of $7.1 ...
Breaking Medicine Technology:Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2Global Respiratory Devices Market 2014-2018 2Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12
... Attached is a press release issued yesterday by GlaxoSmithKline (GSK), ... the American Diabetes Association 69th Scientific Sessions in New Orleans. ... ) , , Syncria is a biological product ... human GLP-1 peptide, and is designed to act throughout the ...
... , Oral Presentation Details Dose Optimization of Pre-Clinical ... 8 Tolerx, Inc., a biopharmaceutical company engaged ... for immune-mediated diseases, today presented results from a ... its Phase 3 anti-CD3 monoclonal antibody, otelixizumab, at ...
Cached Medicine Technology:FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight 2FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight 3Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 2Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 3
(Date:7/30/2014)... According to the Yeast Infection No More book review ... will help candida sufferers get rid of their yeast ... to readers the truth about yeast infection and the real ... will discover natural and safe remedies to relieve symptoms of ... irritation of the vagina or vulva. , Vkool reveals ...
(Date:7/30/2014)... July 30, 2014 My Clients ... over 80 different electronic therapy note templates. Healthcare ... and other computing devices all while meeting the ... or electronic medial records (EMR) consist of psychological ... other essential categories. SOAP and DAP note ...
(Date:7/30/2014)... July 30, 2014 Regents Health Resources, ... services, has brought health care industry veteran Daryl Demonbreun ... to help lead the company’s ambitious plans to grow ... Health has been moving along at a steady pace ... it up a notch,” says Bob Maier, founder and ...
(Date:7/29/2014)... July 30, 2014 Recently, iFitDress.com, a well-known ... of satin bridal gowns . Aside from this, it ... prices, up to 68 percent off. All of its old ... , The company’s sales representative says excitedly, “We are pleased ... the new range, there are a lot of amazing items. ...
(Date:7/29/2014)... Dignity Sciences Limited, a privately held biopharmaceutical company, ... trial with DS107G, an oral formulation of Dihomo Gamma ... placebo-controlled, double-blind, single-ascending and multiple dose Phase I clinical ... food on DS107G in healthy subjects. , The ... both single and multiple oral doses over 28 days, ...
Breaking Medicine News(10 mins):Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 2Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 3Health News:My Clients Plus Announces Over 80 Online Therapy Notes to Help Healthcare Providers Go Paperless 2Health News:Sferrella and Demonbreun Join Regents Health Resources 2Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2
... Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced ... Annual Healthcare Conference will be webcast,live and may ... the Company,s,website, http://www.millennium.com ., (Logo: ... an update on VELCADE(R) (bortezomib) for,Injection and product ...
... Precyse to a leadership role, in Health Information ... Costs ... Precyse Solutions, the leader in,driving peak performance within Health ... as Senior Vice,President and Chief Information Officer. Joining Precyse in ...
... Acute Pain Prescription Drug ... ... Labopharm Inc. (TSX: DDS;,NASDAQ: DDSS) today announced that it has begun ... product (study 06CCL3-001)., "Tramadol-acetaminophen combination products have become widely,prescribed based ...
... 8 a.m. EDT, SHENZHEN, China, March 10 /Xinhua-PRNewswire-FirstCall/ ... ("Nepstar" or "the Company"), the,largest drugstore chain in China ... that it will report financial results for the,fourth quarter ... market,opens on March 19, 2008., The Company will ...
... March 10 Tea-based ingredients are now ... Colorado-based Sage,Group(R), a self-described ,tea think-tank, notes ... outnumber beverage,tea offerings on a global basis. ... other tea derivatives are being formulated into,thousands ...
... March 10 On March 23, the Easter,Bunny will ... goodies.,But, if you,re one of the lucky recipients, make ... your pets. Chocolate is poisonous to,dogs and cats, and ... equally as dangerous., Dr. Gregory S. Hammer, president ...
Cached Medicine News:Health News:Cowen & Company 28th Annual Healthcare Conference to Webcast Millennium Presentation 2Health News:Precyse Solutions Promotes Ken Lacy to Senior Vice President & CIO to Drive Advancement of PrecyseNet(TM), Precyse's Advanced Technology Solution 2Health News:Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen 2Health News:Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen 3Health News:China Nepstar Chain Drugstore to Announce Fourth Quarter 2007 Financial Results on March 19 2Health News:China Nepstar Chain Drugstore to Announce Fourth Quarter 2007 Financial Results on March 19 3Health News:Tea Ingredients Publication Serves Robust Global Demand for Tea-Based Products 2Health News:Tea Ingredients Publication Serves Robust Global Demand for Tea-Based Products 3Health News:AVMA: Keep Pets Safe This Easter 2
... The Vasotrax is an ... pressure and heart rate non-invasively, ... fact, significantly more accurate than ... On a full battery charge, ...
... Inhibins are heterodimeric proteins that suppress the ... the pituitary. Inhibin consists of two distinct ... together. Inhibin A consists of the alpha-subunit ... alpha-subunit and betaB-subunit. Only the dimeric forms ...
... II (IGF-II) is a 7.5 kDa peptide which ... postulated to have mitogenic and metabolic actions involved ... mediated by binding to target cell receptors. IGF-II ... IGF receptor, a monomeric protein which also serves ...
... A (PAPP-A) is a large placenta-derived ... high concentrations by placental trophoblast cells, ... circulation in increasing concentrations throughout gestation ... specific to pregnancy since measurable levels ...
Medicine Products: